Deferiprone exerts a dose‐dependent reduction of liver iron in adults with iron overload. (30th May 2019)

• Record Type: Journal Article
• Authors: Binding, Andrew; Ward, Richard; Tomlinson, George; Kuo, Kevin H. M.
• Is Part Of: European journal of haematology. Volume 103:Number 2(2019)
• Page Start: 80
• Page End: 87
• Publication Date: 2019-05-30
• Subjects: chelation -- deferiprone -- iron overload -- liver -- thalassemia; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13244
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Objective: While doses of deferiprone up to 75 mg/kg/d have been demonstrated to be effective in cardiac iron removal, their efficacy in the reduction of liver iron has been equivocal. The aim of this study was to evaluate the effect of deferiprone dose on liver iron concentrations in adult iron overload patients. Methods: A single‐centered, retrospective, cohort observational study was conducted involving 71 patients exposed to deferiprone doses up to 113 mg/kg/d between January 2009 and June 2015 for a median of 33 months. Results: At the end of the study period, liver iron measured by R2 MRI was reduced by a mean 1.7 mg/g dw. A dose effect was observed, with incremental reductions of 2.8 mg/g dw in end of study LIC for every 10 mg/kg/d higher dose of deferiprone ( P < 0.001). A dose effect was also observed in end of study ferritin and cardiac iron concentration measured by T2* MRI ( P < 0.0001 and P = 0.048, respectively). No associations between adverse effects and deferiprone dose were observed, but there was a trend toward higher rates of agranulocytosis at higher doses and two of three hereditary hemochromatosis patients developed this complication. Conclusion: The present study failed to demonstrate that the use of deferiprone at >90 mg/kg/d was associated with increased risk of agranulocytosis or neutropenia, but did demonstrate more effective liver iron control in iron overload patients.